Characteristics of Activated Monocyte Phenotype Support R5-Tropic Human Immunodeficiency Virus
- PMID: 19997535
- PMCID: PMC2789571
- DOI: 10.4137/iii.s2011
Characteristics of Activated Monocyte Phenotype Support R5-Tropic Human Immunodeficiency Virus
Abstract
BACKGROUND: Microbial translocation has been recognized as an important factor in monocyte activation and contributing to AIDS pathogenesis with elevated plasma lipopolysaccharide (LPS) levels, as a marker for microbial translocation, seen in advanced HIV disease. Therefore, the current study was undertaken to assess monocyte activation in vitro by LPS and to determine its impact on monocyte phenotype. METHODS: Monocytes from non-HIV-infected donors were analyzed for CD14, CD16, CD69, TNFα, and CCR5 by flow cytometry pre- and post-stimulation with LPS. In-vitro cultures were then set up to expose non-activated and activated monocytes to R5-, X4-, and dual (R5/X4)-tropic viruses; and the amount of HIV present on the cells was assayed. RESULTS: Non-HIV-infected monocytes, after LPS stimulation, were confirmed to have an activated phenotype with increase in CD16 and CD69 surface expressions (p<0.05). The activation phenotype was supported by increase in TNFα production, p<0.05. The activated monocytes had increased surface CCR5 (from 21% to 98%; p=0.05); and were found to have more R5-tropic virus than non-activated monocytes (p<0.05). CONCLUSIONS: Following activation by LPS, non-HIV-infected monocytes were found to have increase in surface CCR5. These activated monocytes, when exposed to R5-tropic virus, were found to have more virus compared to non-activated monocytes. The significance of the findings could lie in explaining how microbial translocation plays a role in HIV progression; and possibly promoting CCR5-directed strategies in treating HIV.
Figures


Similar articles
-
Inhibition of dual/mixed tropic HIV-1 isolates by CCR5-inhibitors in primary lymphocytes and macrophages.PLoS One. 2013 Jul 9;8(7):e68076. doi: 10.1371/journal.pone.0068076. Print 2013. PLoS One. 2013. PMID: 23874501 Free PMC article.
-
HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro.Antiviral Res. 2011 Apr;90(1):42-53. doi: 10.1016/j.antiviral.2011.02.005. Epub 2011 Feb 22. Antiviral Res. 2011. PMID: 21349294
-
Purifying selection of CCR5-tropic human immunodeficiency virus type 1 variants in AIDS subjects that have developed syncytium-inducing, CXCR4-tropic viruses.J Gen Virol. 2006 May;87(Pt 5):1285-1294. doi: 10.1099/vir.0.81722-0. J Gen Virol. 2006. PMID: 16603531
-
Differential effects of R5 and X4 human immunodeficiency virus type 1 infection on CD4+ cell proliferation and activation.J Gen Virol. 2005 Apr;86(Pt 4):1171-1179. doi: 10.1099/vir.0.80674-0. J Gen Virol. 2005. PMID: 15784911
-
Maraviroc: a review of its use in HIV infection and beyond.Drug Des Devel Ther. 2015 Oct 1;9:5447-68. doi: 10.2147/DDDT.S90580. eCollection 2015. Drug Des Devel Ther. 2015. PMID: 26491256 Free PMC article. Review.
Cited by
-
The Biology of Monocytes and Dendritic Cells: Contribution to HIV Pathogenesis.Viruses. 2018 Feb 6;10(2):65. doi: 10.3390/v10020065. Viruses. 2018. PMID: 29415518 Free PMC article. Review.
-
Machine learning links different gene patterns of viral infection to immunosuppression and immune-related biomarkers in severe burns.Front Immunol. 2022 Nov 28;13:1054407. doi: 10.3389/fimmu.2022.1054407. eCollection 2022. Front Immunol. 2022. PMID: 36518755 Free PMC article.
-
Translational research in NeuroAIDS: a neuroimmune pharmacology-related course.J Neuroimmune Pharmacol. 2011 Mar;6(1):80-8. doi: 10.1007/s11481-010-9222-y. Epub 2010 May 25. J Neuroimmune Pharmacol. 2011. PMID: 20496178 Free PMC article.
-
Cognitive performance related to HIV-1-infected monocytes.J Neuropsychiatry Clin Neurosci. 2012 Winter;24(1):71-80. doi: 10.1176/appi.neuropsych.11050109. J Neuropsychiatry Clin Neurosci. 2012. PMID: 22450616 Free PMC article.
-
Failure to clear intra-monocyte HIV infection linked to persistent neuropsychological testing impairment after first-line combined antiretroviral therapy.J Neurovirol. 2012 Feb;18(1):69-73. doi: 10.1007/s13365-011-0068-8. Epub 2011 Dec 30. J Neurovirol. 2012. PMID: 22207583 Free PMC article.
References
-
- Kusdra L, McGuire D, Pulliam L. Changes in monocyte/macrophage neurotoxicity in the era of HAART: implications for HIV-associated dementia. Aids. 2002;16:31–38. - PubMed
-
- Williams KC, Hickey WF. Central nervous system damage, monocytes and macrophages, and neurological disorders in AIDS. Annu Rev Neurosci. 2002;25:537–562. - PubMed
-
- Gorry PR, Taylor J, Holm GH, Mehle A, Morgan T, Cayabyab M, Farzan M, Wang H, Bell JE, Kunstman K, Moore JP, Wolinsky SM, Gabuzda D. Increased CCR5 affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human immunodeficiency virus type 1 isolate. J Virol. 2002;76:6277–6292. - PMC - PubMed
-
- Kaufmann A, Salentin R, Gemsa D, Sprenger H. Increase of CCR1 and CCR5 expression and enhanced functional response to MIP-1 alpha during differentiation of human monocytes to macrophages. J Leukoc Biol. 2001;69:248–252. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials